<SEC-DOCUMENT>0001206774-17-001584.txt : 20170509
<SEC-HEADER>0001206774-17-001584.hdr.sgml : 20170509
<ACCEPTANCE-DATETIME>20170509161034
ACCESSION NUMBER:		0001206774-17-001584
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170509
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170509
DATE AS OF CHANGE:		20170509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		17826505

	BUSINESS ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>geron31261311-8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>
<BR>

<P align=center><B><FONT face="Times New Roman" size=2>UNITED
STATES<BR></FONT></B><B><FONT face="Times New Roman" size=2>SECURITIES AND
EXCHANGE COMMISSION<BR>WASHINGTON, D.C. 20549 <BR>___________</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>FORM 8-K </FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>CURRENT
REPORT<BR></FONT></B><B><FONT face="Times New Roman" size=2>PURSUANT TO SECTION
13 OR 15(d) OF THE<BR>SECURITIES EXCHANGE ACT OF 1934</FONT></B><FONT face="Times New Roman" size=2> </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>Date of Report (Date of
earliest event reported): </FONT><B><FONT face="Times New Roman" size=2>May 9,
2017</FONT></B><FONT face="Times New Roman" size=2> </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>GERON
CORPORATION</FONT></B><FONT face="Times New Roman" size=2> <BR></FONT><FONT face="Times New Roman" size=2>(Exact name of registrant as specified in its
charter) </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><B><FONT face="Times New Roman" size=2>Delaware</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><B><FONT face="Times New Roman" size=2>0-20859</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><B><FONT face="Times New Roman" size=2>75-2287752</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>(State or other jurisdiction</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>(Commission File Number)</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>(IRS Employer</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>of incorporation)</FONT></TD>
    <TD noWrap align=left width="33%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>Identification
No.)</FONT></TD></TR></TABLE><BR>
<P align=center><B><FONT face="Times New Roman" size=2>149 COMMONWEALTH DRIVE,
SUITE 2070<BR>MENLO PARK, CALIFORNIA 94025 <BR></FONT></B><FONT face="Times New Roman" size=2>(Address of principal executive offices, including
zip code) </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>(650)
473-7700<BR></FONT></B><FONT face="Times New Roman" size=2>(Registrant&#146;s
telephone number, including area code) </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>N/A <BR></FONT></B><FONT face="Times New Roman" size=2>(Former name or former address, if changed since
last report) </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions: </FONT></P>
<TABLE style="LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2><FONT style="FONT-FAMILY: Wingdings">o</FONT></FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD vAlign=top align=left width="98%"><FONT face="Times New Roman" size=2>Written communications pursuant to Rule 425 under the Securities
      Act (17 CFR 230.425)</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="98%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2><FONT style="FONT-FAMILY: Wingdings">o</FONT></FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="98%"><FONT face="Times New Roman" size=2>Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="98%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2><FONT style="FONT-FAMILY: Wingdings">o</FONT></FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="98%"><FONT face="Times New Roman" size=2>Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="98%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2><FONT style="FONT-FAMILY: Wingdings">o</FONT></FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="98%"><FONT face="Times New Roman" size=2>Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><B><FONT face="Times New Roman" size=2>Item 2.02 Results of
Operations and Financial Condition </FONT></B></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Geron Corporation (the
&#147;Company&#148;) is furnishing this information under Item 2.02 of Form 8-K.
</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The information in this
Current Report, including Exhibit 99.1, is being furnished and shall not be
deemed &#147;filed&#148; for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities
of that section. The information in this Current Report, including Exhibit 99.1,
shall not be incorporated by reference into any registration statement or other
document filed pursuant to the Securities Act of 1933, as amended, or the
Exchange Act. </FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>On May 9, 2017, the Company
issued a press release announcing its financial results for the three months
ended March 31, 2017. A copy of the press release is attached as Exhibit 99.1.
</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Item 9.01 Financial
Statements and Exhibits</FONT></B></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>(d) Exhibits </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=2>Exhibit
    No.</FONT></B></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%; border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="100%"><B><FONT face="Times New Roman" size=2>Description</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>99.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="100%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Press release dated May 9,
2017.</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>1</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>SIGNATURE </FONT></B></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="49%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="50%" colSpan=3><FONT face="Times New Roman" size=2>GERON CORPORATION</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;May 9,
      2017</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>By:</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="25%"><FONT face="Times New Roman" size=2>/s/ Stephen N. Rosenfield</FONT></TD>
    <TD noWrap align=left width="24%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>Name:&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=left width="49%" colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>Title:</FONT></TD>
    <TD noWrap align=left width="49%" colSpan=2><FONT face="Times New Roman" size=2>Executive Vice President, General Counsel
      and</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="49%" colSpan=2><FONT face="Times New Roman" size=2>Corporate
Secretary</FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>EXHIBIT INDEX
</FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=2>Exhibit
No.</FONT></B></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%; border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="97%"><B><FONT face="Times New Roman" size=2>Description</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>99.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="97%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Press release dated May 9,
  2017.</FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>geron31261311-ex991.htm
<DESCRIPTION>PRESS RELEASE DATED MAY 9, 2017
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>
<BR>
<P align=right><B><FONT face="Times New Roman" size=2>EXHIBIT</FONT></B><B><FONT face="Times New Roman" size=2> </FONT></B><B><FONT face="Times New Roman" size=2>99.1 </FONT></B></P>
<P align=center><B><FONT style="FONT-VARIANT: small-caps" face="Times New Roman" size=2>Press Release Dated May 9, 2017</FONT></B></P><IMG src="geron31261311-ex991x1x1.jpg" border=0><BR>
<P align=center><B><FONT face="Times New Roman" size=2>Geron Corporation Reports
First Quarter 2017 Financial Results and Recent Events </FONT></B></P>
<P align=left><B><FONT face="Times New Roman" size=2>MENLO PARK,
Calif.,</FONT></B><B><FONT face="Times New Roman" size=1> </FONT></B><B><FONT face="Times New Roman" size=2>May 9, 2017 </FONT></B><FONT face="Times New Roman" size=2>-- Geron Corporation (Nasdaq: GERN) today reported
financial results for the first quarter ended March 31, 2017 and recent events.
</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>First Quarter 2017 Results
</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>For the first quarter of 2017,
the company reported operating revenues of $537,000 and operating expenses of
$8.0 million compared to $749,000 and $9.8 million, respectively, for the
comparable 2016 period. Revenues for the first quarter of 2017 and 2016 included
royalty and license fee revenues under various non-imetelstat license
agreements. Net loss for the first quarter of 2017 was $7.2 million, or $0.05
per share, compared to $8.8 million, or $0.06 per share, for the comparable 2016
period. The company ended the first quarter of 2017 with $121.7 million in cash
and investments. </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Research and development
expenses for the three months ended March 31, 2017 and 2016 were $3.4 million
and $5.0 million, respectively, and largely reflect the company&#146;s proportionate
share of clinical development expenses under the imetelstat collaboration with
Janssen Biotech, Inc. (Janssen). Higher research and development expenses in
2016 were primarily due to start-up costs for the initiation of IMerge, the
Phase 2/3 trial in myelodysplastic syndromes being conducted by Janssen, in
which the first patient was dosed in January 2016. </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>General and administrative
expenses for the three months ended March 31, 2017 and 2016 were $4.7 million
and $4.8 million, respectively. The decrease in general and administrative
expenses in 2017 compared to 2016 primarily reflects reduced consulting costs.
</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Interest and other income for
the three months ended March 31, 2017 and 2016 were $332,000 and $256,000,
respectively. The increase in interest and other income in 2017 compared to 2016
primarily reflects higher yields on the company&#146;s marketable securities
portfolio. </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>&#147;As a result of the second
internal data reviews that were completed in April for the imetelstat clinical
trials in myelodysplastic syndromes and myelofibrosis, both trials are
continuing unmodified. For IMerge, the next step is a decision regarding the
Phase 3 portion of the trial. If Janssen decides to move forward, we expect the
Phase 3 portion to be open to patient enrollment in the fourth quarter. For
IMbark, we expect Janssen to evaluate maturing data from the trial during the
next year, including an assessment of overall survival,&#148; said John A. Scarlett,
M.D., Geron&#146;s President and Chief Executive Officer. &#147;We continue to be pleased
by the commitment to imetelstat shown by our colleagues at Janssen. Their
conduct of these internal data reviews has highlighted to us the care and
professional development expertise they are applying to this innovative drug.&#148;
</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Recent Company Events
</FONT></B></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>Imetelstat Clinical
Development</FONT></I></B><FONT face="Times New Roman" size=2> </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>The telomerase inhibitor
imetelstat is being evaluated in two ongoing clinical trials, IMerge and IMbark,
as conducted by Janssen under the terms of an exclusive worldwide license and
collaboration agreement. IMerge is a Phase 2/3 clinical trial designed to
evaluate imetelstat in transfusion dependent patients with IPSS low or
intermediate-1 risk myelodysplastic syndromes (MDS) who have relapsed after or
are refractory to prior treatment with an
erythropoiesis stimulating agent (ESA). IMbark is a Phase 2 clinical trial
designed to evaluate two dose levels of imetelstat in patients with
intermediate-2 or high risk myelofibrosis (MF) who have relapsed after or are
refractory to prior treatment with a JAK inhibitor. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>1 </FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2>In April 2017, the second
internal data reviews of IMerge and IMbark were completed. Based on these
reviews, the Joint Steering Committee determined the following: </FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2>Both trials continue
      unmodified, and patients remaining in the treatment phases may continue to
      receive imetelstat.</FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%">&nbsp;</TD>
    <TD vAlign=top width="99%"></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2>The safety profile of
      imetelstat in both trials was consistent with prior clinical trials of
      imetelstat in hematologic malignancies, and no new safety signals were
      identified.</FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%">&nbsp;</TD>
    <TD vAlign=top width="99%"></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><B><FONT face="Times New Roman" size=2>For IMerge, the
      benefit/risk profile of imetelstat in the Phase 2 patients supports
      continued development in lower risk MDS.</FONT></B><FONT face="Times New Roman" size=2> A data package and proposed design
      refinements to the Phase 3 component of the trial are planned to be
      provided to the FDA. In addition, the Phase 2 data from IMerge are
      expected to be submitted for consideration for presentation at a medical
      conference in the future. </FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%">&nbsp;</TD>
    <TD vAlign=top width="99%"></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><B><FONT face="Times New Roman" size=2>For IMbark, the
      current results suggest clinical benefit and a potential overall survival
      benefit associated with imetelstat treatment in relapsed or refractory
      MF.</FONT></B><FONT face="Times New Roman" size=2> Enrollment of new
      patients to the trial remains suspended because the total number of
      patients enrolled to date is adequate to assess longer-term outcome
      measures, including overall survival, when the data are fully matured.
      </FONT></P></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman" size=2>Geron expects further
decisions by Janssen on the development of imetelstat will be informed by
maturing efficacy and safety data from the trials, feedback from health
authorities, and the totality of imetelstat program information, including an
assessment of the evolving treatment landscapes in MDS and MF and the potential
application of imetelstat in multiple hematologic malignancies. </FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>Poster
Presentation</FONT></I></B><FONT face="Times New Roman" size=2> </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Non-clinical data on
imetelstat was presented as a poster by Janssen at the 2017 annual meeting of
the American Association for Cancer Research in April: </FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><U><FONT face="Times New Roman" size=2>Telomerase inhibitor
      imetelstat in combination with the BCL-2 inhibitor venetoclax enhances
      apoptosis in vitro and increases survival
      in vivo in acute myeloid leukemia (Abstract #1101)</FONT></U></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%">&nbsp;</TD>
    <TD vAlign=top width="99%"></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2>Data presented described
      non-clinical results of </FONT><FONT face="Times New Roman" size=2>i</FONT><FONT face="Times New Roman" size=2>metelstat&#146;s activity in
      combination with venetoclax, a selective BCL-2 inhibitor. In acute myeloid
      leukemia (AML) cell lines, telomerase expression and activity were
      decreased by imetelstat and further reduced in combination with
      venetoclax. In addition, imetelstat enhanced apoptosis induced by
      venetoclax in AML cell lines and AML patient samples. Combining imetelstat
      with venetoclax in an AML mouse model prolonged survival, with four of ten
      mice alive approximately 80 days after treatment was stopped.
    </FONT></P></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman" size=2>The poster is available on
Geron&#146;s website at www.geron.com/presentations.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Annual Meeting of
Stockholders </FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Geron&#146;s Annual Meeting of
Stockholders will be held at 4:00 p.m. PDT / 7:00 p.m. EDT today, May 9, 2017.
Further information about the Annual Meeting is available on Geron&#146;s website at
www.geron.com on the homepage and in the Investors section under Events.
</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Due to the timing of the
Annual Meeting this year, Geron management will not be hosting a separate first
quarter conference call.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>2</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><B><FONT face="Times New Roman" size=2>About Geron </FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Geron is a biopharmaceutical
company supporting the clinical stage development of a first-in-class telomerase
inhibitor, imetelstat, in hematologic myeloid malignancies. For more information
about Geron, visit www.geron.com. </FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Use of Forward-Looking
Statements </FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Except for the historical
information contained herein, this press release contains forward-looking
statements made pursuant to the &#147;safe harbor&#148; provisions of the Private
Securities Litigation Reform Act of 1995. Investors are cautioned that
statements in this press release regarding: (i) continued development of
imetelstat by Janssen for MDS in the Phase 3 portion of IMerge and continued
conduct by Janssen of IMbark and/or IMerge; (ii) data that suggest clinical
benefit and potential overall survival benefit of imetelstat in MF; (iii) a
planned data package will be provided to the FDA for IMerge; (iv) that Janssen
will evaluate more mature data including overall survival for IMbark; (v)
potential outcomes of any data reviews conducted by Janssen for IMbark; (vi) any
future presentation of data from current clinical trials of imetelstat by
Janssen at a medical conference; (vii) the safety and efficacy of imetelstat; (viii) that if Janssen decides to proceed with the Phase 3 portion of
IMerge, the clinical trial will be opened for patient enrollment in the fourth
quarter of 2017; and (ix) other statements that are not historical facts,
constitute forward-looking statements. These statements involve risks and
uncertainties that can cause actual results to differ materially from those in
such forward-looking statements. These risks and uncertainties, include, without
limitation, risks and uncertainties related to: (i) whether Janssen decides to
initiate the Phase 3 portion of IMerge and to continue to conduct IMerge and/or
IMbark; (ii) whether imetelstat is safe and efficacious and will succeed in
IMbark and/or IMerge by overcoming all of the clinical safety and efficacy,
technical, scientific, manufacturing and regulatory challenges; (iii) whether
health authorities permit IMbark and/or IMerge to continue to proceed under the
existing protocols or any amendments thereto; (iv) Janssen&#146;s ability to collect
additional and more mature data from current clinical trials of imetelstat; (v)
Geron&#146;s dependence on Janssen for the development, regulatory approval,
manufacture and commercialization of imetelstat, including the risks that if
Janssen were to breach or terminate the collaboration agreement or otherwise
fail to successfully develop and commercialize imetelstat and in a timely
manner, or at all, Geron would not obtain the anticipated financial and other
benefits of the collaboration agreement with Janssen and the clinical
development or commercialization of imetelstat could be delayed or terminated;
(vi) any future efficacy or safety results from any clinical trial of imetelstat
may cause the benefit/risk profile of imetelstat to become unacceptable; and
(vii) patent coverage of imetelstat enables Janssen to successfully
commercialize imetelstat. Additional information on the above-stated risks and
uncertainties and additional risks, uncertainties and factors that could cause
actual results to differ materially from those in the forward-looking statements
are contained in Geron&#146;s periodic reports filed with the Securities and Exchange
Commission under the heading &#147;Risk Factors,&#148; including Geron&#146;s quarterly report
on Form 10-Q for the quarter ended March 31, 2017. Undue reliance should not be
placed on forward-looking statements, which speak only as of the date they are
made, and the facts and assumptions underlying the forward-looking statements
may change. Except as required by law, Geron disclaims any obligation to update
these forward-looking statements to reflect future information, events or
circumstances. </FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>CONTACT: </FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Anna Krassowska,
Ph.D.<BR>Investor and Media
Relations<BR>650-473-7765<BR>investor@geron.com<BR>media@geron.com </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Financial table follows.
</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>3</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>GERON
CORPORATION<BR></FONT></B><B><FONT face="Times New Roman" size=2>CONDENSED
STATEMENTS OF OPERATIONS<BR>(UNAUDITED) </FONT></B></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="93%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=5><B><FONT face="Times New Roman" size=2>Three Months Ended March
      31,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%"><I><FONT face="Times New Roman" size=2>(In thousands, except share and per share data)</FONT></I></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>2017</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>2016</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Revenues:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;License fees and
      royalties</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>537</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>749</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=7>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Operating expenses:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and
      development</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>3,374</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>5,033</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and
      administrative</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>4,657</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>4,793</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
      operating expenses</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>8,031</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>9,826</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Loss from operations</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(7,494)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(9,077)</FONT></TD></TR>
  <TR>
    <TD width="99%" bgColor=#cceeff colSpan=7>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%"><FONT face="Times New Roman" size=2>Interest and other income</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>332</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>256</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Interest and other expense</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(21)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(21)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%"><FONT face="Times New Roman" size=2>Net
      loss</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%; padding-bottom: 1pt"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD NOWRAP STYLE="text-align: right; width: 1%; border-bottom: Black 2pt double"><FONT face="Times New Roman" size=2>(7,183)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%; padding-bottom: 1pt"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD NOWRAP STYLE="text-align: right; width: 1%; border-bottom: Black 2pt double"><FONT face="Times New Roman" size=2>(8,842)</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=7>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#cceeff><B><FONT face="Times New Roman" size=2>Basic and diluted net loss per
      share:</FONT></B></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss per
    share</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="PADDING-BOTTOM: 1pt; WIDTH: 1%; TEXT-ALIGN: left" noWrap width="1%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>(0.05)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="PADDING-BOTTOM: 1pt; WIDTH: 1%; TEXT-ALIGN: left" noWrap width="1%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>(0.06)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares used in computing
      net loss per share</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>159,161,550</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>158,896,038</FONT></TD></TR></TABLE></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>CONDENSED BALANCE SHEETS
</FONT></B></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>March 31,</FONT></B></TD>
    <TD style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>December 31,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"><I><FONT face="Times New Roman" size=2>(In thousands)</FONT></I></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>2017</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>2016</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>(Unaudited)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>(Note 1)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Current assets:</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash, cash
      equivalents and restricted cash</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>15,129</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>13,078</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current marketable
      securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>84,432</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>102,035</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current
      assets</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>7,002</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>999</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
      current assets</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>106,563</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>116,112</FONT></TD></TR>
  <TR>
    <TD width="100%" bgColor=#cceeff colSpan=7>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"><FONT face="Times New Roman" size=2>Noncurrent marketable securities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>22,126</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>13,954</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Property and equipment, net</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>158</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>183</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%; padding-bottom: 1pt"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>128,847</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%; padding-bottom: 1pt"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>130,249</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=7>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Current liabilities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>11,596</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>7,869</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%"><FONT face="Times New Roman" size=2>Stockholders&#146; equity</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>117,251</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>122,380</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="94%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%; background-color: #cceeff; padding-bottom: 1pt"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>128,847</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%; background-color: #cceeff; padding-bottom: 1pt"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>130,249</FONT></TD></TR></TABLE></DIV><BR>
<TABLE style="WIDTH: 100%; LINE-HEIGHT: NORMAL; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 border=0>

  <TR vAlign=bottom>
    <TD NOWRAP STYLE="width: 1%; text-align: left; vertical-align: top">
      <P align=left><B><FONT face="Times New Roman" size=2>Note
      1</FONT></B><FONT face="Times New Roman" size=2>:</FONT></P></TD>
    <TD STYLE="width: 1%; text-align: left; vertical-align: top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 100%; text-align: left; vertical-align: top">
      <P align=left><FONT face="Times New Roman" size=2>Derived from audited
      financial statements included in the company&#146;s annual report on Form 10-K
      for the year ended December 31,
2016.</FONT></P></TD></TR></TABLE>



<P align=center><FONT face="Times New Roman" size=2>###</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>geron31261311-ex991x1x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron31261311-ex991x1x1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  S & # 2(  A$! Q$!_\0
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M]M;Z?)XC]O\ ^"&O_*Q#_P %].2?^*W\;_\ K0&H8_\ K>@_3S?_ (.2B?\
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M;%\!/_55>%* /Y-?^#,[_D7/^"H__9R?P[_](/BA7G?_  4W_P"5OG_@E_\
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M^!?"_A_P=X9T\RR3FP\/^&-)M-$T:S,\I:68VVG65M 9I6:239O=BS,3U-%
M'\CW_!J;^R1^T[^RIH/_  44@_:3^ WQ2^!TWQ%^/G@;7_ D7Q-\':QX1D\7
M:)8V?Q$2\U705U:VMSJ5E;-J-@L]Q;;XXVN[<,09%SPO_!0;]CO]JGX@_P#!
MT%_P3Q_:@\#_ +/OQ:\5_L[?#SX??!K3?'7QIT'P5K>H_#CPG?:/XD^.USJM
MIKWBJVM7TO39].M]=T6:\2XN$-O'J=DTFT3IG^QNB@#XU_;8_P""?G[(O_!1
M7X=>&/A-^V1\)/\ A</P_P#!OC6W^(GAO0/^$]^)OP^_LWQC::'K?ANWUC^U
M?A9XS\$:W>>7HOB/6;+^S[_4KK2W^V?:7L6N[>UG@M?L?_L!?L;_ + O@JX\
M ?LA_L_>!/@IH-^[/K%YH<.J:WXR\2$W$MU$/%OQ&\8:EXB^(?B]+.6:0:;%
IXG\4:M'I<+"VTY+6V58E** /L"BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
